Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity

Hilary Nicholson, Anthony Comeau, Christophe Mesangeau, Christopher R. McCurdy and Wayne D. Bowen
Journal of Pharmacology and Experimental Therapeutics August 2015, 354 (2) 203-212; DOI: https://doi.org/10.1124/jpet.115.224105
Hilary Nicholson
Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island (H.N., A.C., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Comeau
Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island (H.N., A.C., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Mesangeau
Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island (H.N., A.C., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. McCurdy
Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island (H.N., A.C., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne D. Bowen
Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, Rhode Island (H.N., A.C., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The sigma-2 receptors are promising therapeutic targets because of their significant upregulation in tumor cells compared with normal tissue. Here, we characterize CM572 [3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one] (sigma-1 Ki ≥ 10 µM, sigma-2 Ki = 14.6 ± 6.9 nM), a novel isothiocyanate derivative of the putative sigma-2 antagonist, SN79 [6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one]. CM572 bound irreversibly to sigma-2 receptors by virtue of the isothiocyanate moiety but not to sigma-1. Studies in human SK-N-SH neuroblastoma cells revealed that CM572 induced an immediate dose-dependent increase in cytosolic calcium concentration. A 24-hour treatment of SK-N-SH cells with CM572 induced dose-dependent cell death, with an EC50 = 7.6 ± 1.7 µM. This effect was sustained over 24 hours even after a 60-minute pretreatment with CM572, followed by extensive washing to remove ligand, indicating an irreversible effect consistent with the irreversible binding data. Western blot analysis revealed that CM572 also induced cleavage activation of proapoptotic BH3-interacting domain death agonist. These data suggest irreversible agonist-like activity. Low concentrations of CM572 that were minimally effective were able to attenuate significantly the calcium signal and cell death induced by the sigma-2 agonist CB-64D [(+)-1R,5R-(E)-8-benzylidene-5-(3-hydroxyphenyl)-2-methylmorphan-7-one]. CM572 was also cytotoxic against PANC-1 pancreatic and MCF-7 breast cancer cell lines. The cytotoxic activity of CM572 was selective for cancer cells over normal cells, being much less potent against primary human melanocytes and human mammary epithelial cells. Taken together, these data show that CM572 is a selective, irreversible sigma-2 receptor partial agonist. This novel irreversible ligand may further our understanding of the endogenous role of this receptor, in addition to having potential use in targeted cancer diagnosis and therapy.

Footnotes

    • Received March 1, 2015.
    • Accepted May 29, 2015.
  • This work was supported by the National Institutes of Health National Institute of General Medical Sciences T32 Predoctoral Pharmacology Training [Grant 1-T32-GM077995-01A2] (to H.N.); National Institutes of Health National Institute of General Medical Sciences R25 Initiative for Maximizing Student Development [Grant R25-GM083270] (to H.N.); Brown Pharmacia Predoctoral Fellowship (to H.N.); National Institutes of Health National Institute on Drug Abuse Postdoctoral T32 Training [Grant 5T32-DA016184-09] (to A.C.); National Institutes of Health National Institute on Drug Abuse [Grant R01-DA023205] (to C.M. and C.R.M.); National Institutes of Health National Institute of General Medical Sciences [Grant P20-GM104932] (to C.M. and C.R.M.); and the Upjohn Professorship in Pharmacology, Brown University (to W.D.B.).

  • This work has been previously presented in part in the following abstracts: Nicholson H, Comeau A, Mesangeau C, McCurdy CR, and Bowen WD (2013) Development of selective irreversible antagonists for sigma-2 receptors (Abstract 2242). American Association for Cancer Research Annual Meeting; 2013 Apr 6–10; Washington, DC; and Nicholson H, Comeau A, Mesangeau C, McCurdy CR, and Bowen WD (2013) Irreversible modulators of sigma-2 receptor function: Isothiocyanate derivatives of SN79 (Abstract 63.03). Society for Neuroscience Annual Meeting; 2013 Nov 9–13; San Diego, CA.

  • dx.doi.org/10.1124/jpet.115.224105.

  • Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 354 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 354, Issue 2
1 Aug 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

CM572: An Irreversible Sigma-2 Receptor Partial Agonist

Hilary Nicholson, Anthony Comeau, Christophe Mesangeau, Christopher R. McCurdy and Wayne D. Bowen
Journal of Pharmacology and Experimental Therapeutics August 1, 2015, 354 (2) 203-212; DOI: https://doi.org/10.1124/jpet.115.224105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

CM572: An Irreversible Sigma-2 Receptor Partial Agonist

Hilary Nicholson, Anthony Comeau, Christophe Mesangeau, Christopher R. McCurdy and Wayne D. Bowen
Journal of Pharmacology and Experimental Therapeutics August 1, 2015, 354 (2) 203-212; DOI: https://doi.org/10.1124/jpet.115.224105
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sodium Pentobarbital Suppresses Breast Cancer
  • Off-Target Effect of PDE Inhibitors on Colon Cancer
  • Ixazomib Suppresses Esophageal Squamous Cell Carcinoma
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics